Want to see CH:MOLN full AI Analyst Report?
Molecular Partners AG (MOLN) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| [212Pb]Pb-Mp0712, [203Pb]Pb-Mp0712 | Small Cell Lung Cancer (Sclc), Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma Of The Lung (Lcnec), Extrapulmonary Neuroendocrine Carcinoma (Ep-Nec), Gastroenteropancreatic Nec (Gep Nec), Nec Of The Bladder, Other Dll3 Expressing Epnec | phase1AndPhase2 | Recruiting | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | Nov 10, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| [212Pb]Pb-Mp0712, [203Pb]Pb-Mp0712 | phase1AndPhase2 | Small Cell Lung Cancer (Sclc), Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma Of The Lung (Lcnec), Extrapulmonary Neuroendocrine Carcinoma (Ep-Nec), Gastroenteropancreatic Nec (Gep Nec), Nec Of The Bladder, Other Dll3 Expressing Epnec | Recruiting | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | Nov 10, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Molecular Partners (CH:MOLN) have in its pipeline
Molecular Partners AG CH:MOLN is currently developing the following drugs: [212Pb]Pb-Mp0712, [203Pb]Pb-Mp0712. These drug candidates are in various stages of clinical development as the company works toward FDA approval.